AnGes Inc
AnGes, Inc. engages in the research and development of gene-based medical products. It develops HGF gene therapy product for the treatment of ischemic diseases; NF-"B Decoy Oligo DNA for chronic discogenic lumber back pain; and DNA vaccines for the treatment of hypertension and cervical intraepithelial neoplasia, as well as intranasal formulation of the COVID-19 vaccine. The company was formerly … Read more
AnGes Inc (AMGXF) - Net Assets
Latest net assets as of June 2025: $3.40 Billion USD
Based on the latest financial reports, AnGes Inc (AMGXF) has net assets worth $3.40 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.79 Billion) and total liabilities ($2.38 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.40 Billion |
| % of Total Assets | 58.8% |
| Annual Growth Rate | -7.14% |
| 5-Year Change | -93.4% |
| 10-Year Change | N/A |
| Growth Volatility | 81.96 |
AnGes Inc - Net Assets Trend (2017–2024)
This chart illustrates how AnGes Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AnGes Inc (2017–2024)
The table below shows the annual net assets of AnGes Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.16 Billion | -91.74% |
| 2023-12-31 | $26.10 Billion | -14.21% |
| 2022-12-31 | $30.43 Billion | -21.25% |
| 2021-12-31 | $38.63 Billion | +18.22% |
| 2020-12-31 | $32.68 Billion | +171.08% |
| 2019-12-31 | $12.06 Billion | +55.87% |
| 2018-12-31 | $7.73 Billion | +113.55% |
| 2017-12-31 | $3.62 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to AnGes Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4283059400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $48.67 Billion | 2256.86% |
| Total Equity | $2.16 Billion | 100.00% |
AnGes Inc Competitors by Market Cap
The table below lists competitors of AnGes Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Avalue Technology
TWO:3479
|
$135.83 Million |
|
Dong Phu Rubber JSC
VN:DPR
|
$135.84 Million |
|
Anhui Hyea Aromas Co Ltd
SHE:300886
|
$135.87 Million |
|
Vaxart Inc
NASDAQ:VXRT
|
$135.87 Million |
|
Gix Internet Ltd
TA:ALMO
|
$135.71 Million |
|
iOCO Limited
JSE:IOC
|
$135.70 Million |
|
Dar Global Plc
LSE:DAR
|
$135.68 Million |
|
Brii Biosciences Limited
PINK:BRIBF
|
$135.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AnGes Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,103,166,000 to 2,156,590,000, a change of -23,946,576,000 (-91.7%).
- Net loss of 28,128,983,000 reduced equity.
- Share repurchases of 8,000 reduced equity.
- New share issuances of 3,008,401,000 increased equity.
- Other factors increased equity by 1,174,014,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-28.13 Billion | -1304.33% |
| Share Repurchases | $8.00K | -0.0% |
| Share Issuances | $3.01 Billion | +139.5% |
| Other Changes | $1.17 Billion | +54.44% |
| Total Change | $- | -91.74% |
Book Value vs Market Value Analysis
This analysis compares AnGes Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $45.43 | $0.36 | x |
| 2018-12-31 | $78.94 | $0.36 | x |
| 2019-12-31 | $112.70 | $0.36 | x |
| 2020-12-31 | $245.60 | $0.36 | x |
| 2021-12-31 | $252.40 | $0.36 | x |
| 2022-12-31 | $170.33 | $0.36 | x |
| 2023-12-31 | $131.52 | $0.36 | x |
| 2024-12-31 | $7.53 | $0.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AnGes Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1304.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4370.31%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 2.16x
- Recent ROE (-1304.33%) is below the historical average (-199.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -103.94% | -1030.91% | 0.09x | 1.09x | $-4.13 Billion |
| 2018 | -38.74% | -491.21% | 0.08x | 1.04x | $-3.77 Billion |
| 2019 | -31.11% | -1147.89% | 0.03x | 1.04x | $-4.96 Billion |
| 2020 | -12.88% | -10524.30% | 0.00x | 1.17x | $-7.48 Billion |
| 2021 | -35.40% | -21319.14% | 0.00x | 1.18x | $-17.54 Billion |
| 2022 | -39.17% | -18186.03% | 0.00x | 1.28x | $-14.96 Billion |
| 2023 | -28.49% | -4861.66% | 0.01x | 1.11x | $-10.05 Billion |
| 2024 | -1304.33% | -4370.31% | 0.14x | 2.16x | $-28.34 Billion |
Industry Comparison
This section compares AnGes Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AnGes Inc (AMGXF) | $3.40 Billion | -103.94% | 0.70x | $135.73 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |